Melanoma and immunity.
Rheins
L A
LA
University of Cincinnati College of Medicine, Ohio.
Nordlund
J J
JJ
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D015415:Biomarkers; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007157:Immunologic Surveillance; D007372:Interferons / Q000502:physiology / Q000627:therapeutic use; D007376:Interleukin-2 / Q000502:physiology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008545:Melanoma / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology; D011968:Receptors, Histamine / Q000187:drug effects / Q000502:physiology; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018800:Thy-1 Antigens
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015415:Biomarkers; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D011968:Receptors, Histamine; D018800:Thy-1 Antigens; D007372:Interferons